It’s no secret that with the generic patent cliff and a lackluster number of FDA approvals over the past few years, sales numbers across Big Pharma have been down across the board. Nobody’s happy with the numbers, and many companies are responding by banking on increased mergers and acquisitions activity, in hopes that fitting more …
By Tracy Staton Three deals now in the works embody three very different trends. Yet another Japanese drugmaker is expanding westward by snapping up a smaller pharma company. A U.S. company is buying a drug-development firm for access to a potential new med. And a potential sale in the Middle East has fallen into limbo …
By John Carroll It’s not often that a Big Pharma company like AstraZeneca ($AZN) touts its early- or mid-stage drug development program. The odds are stacked too high against success, and there’s a very long road that stretches out before shareholders can begin to glean where the value is likely to come from. But AZ’s high profile …
By John Carroll With all the buzz last week about Sanofi’s new Covance deal and its ongoing struggle to gain control of Genzyme, it was easy to overlook CEO Chris Viehbacher’s pipeline review for the Big Pharma company. Viehbacher has been engaged in a head-to-toe revamp of R&D from his first day at the helm. Late last …
